銀屑病：數字營銷趨勢

Digital Marketing Trends in Psoriasis

出版日期: 2023年01月30日 | 出版商:

GlobalData | 英文 38 Pages | 訂單完成後即時交付

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告評估了銀屑病 (PsO) 藥物資產的關鍵數字營銷指標，包括面向患者和醫療保健專業人員 (HCP) 的品牌網站、移動應用和社交媒體帳戶。指標包括網站流量、參與度、來源、數字展示廣告 (DDA)、付費搜索引擎優化 (SEO)、移動應用下載和社交媒體帖子互動。按國家/地區劃分，包括美國、4EU（意大利、法國、德國、西班牙）、英國和加拿大 (EUCAN)。

AbbVie's Skyrizi.com achieved the highest total traffic across branded PsO patient sites in the US, with almost 7.2 million visitors between January 2022 - December 2022. This was followed by Novartis's Cosentyx.com (3.3 million visits) and AbbVie's Humira.com (2.3 million visits). Amgen spent the most on digital display advertising (DDA) for Otezla.com at approximately $3.8 million, followed by Enbrel.com at approximately $3 million. Cosentyx.com was supported by the most paid search engine optimization (SEO) at over 5,460 keywords, followed by Otezla.com (5,440) and Stelarainfo.com (4,080).

Amgen's Enbrelpro.com achieved the highest traffic across branded PsO HCP sites in the US, with over 483,000 visits between January 2022 - December 2022. This was followed by Amgen's Otezlapro.com (192,000 visits), AbbVie's Skyrizihcp.com (120,000 visits), and BMS' Sotyktuhcp.com (117,000 visits) which only launched in September 2022. For DDA, Amgen spent the most on Enbrelpro.com at approximately $268,000 and Otezlapro.com at $193,000. Otezlapro.com was also supported by the most paid SEO at over 7,800 keywords, followed by Enbrelpro.com (4,100) and BMS's Sotyktuhcp.com (2,220).

AbbVie's Psoriasis.com had the highest traffic of all unbranded PsO sites in the US, with over 299,000 visitors from January 2022 to December 2022. The highest proportion of traffic to unbranded PsO websites in the US originated from direct search, followed by organic. Amgen spent the most on DDA for its Amgeninflammation.com at approximately $10,000, while AbbVie's Psoriasis.com was supported by the most paid SEO at 680 keywords.

Between January 2022 - December 2022, 435 social media posts related to PsO were detected from pharma companies in the US, including Arcutis Biotherapeutics, Eli Lilly, Novartis, AbbVie, Boehringer Ingelheim, and Amgen. The post with the highest interaction (8.7%) was from Arcutis Biotherapeutics Twitter account, which promoted the FDA approval of Zoryve for the treatment of adults and adolescents with plaque PsO.

AbbVie's Abbvie-care.de achieved the highest total traffic across PsO branded sites in EUCAN, with over 751,000 visitors between January 2022 - December 2022. This was followed by Janssen's Askaboutstelara.ca (261,000 visits) and UCB's Ucbcares.de (152,000 visits).

Novartis's German Psoriasis.info site achieved the highest total traffic across PsO unbranded sites in EUCAN, with over 675,000 visitors, followed by Janssen's Psoriasis360.es (531,000 visits) and Psoriasis360.it (213,000 visits). The highest proportion of traffic to unbranded PsO websites originated from organic searches, followed by direct. Novartis's Lapelleconta.it had the most organic traffic (77%), while Janssen's Psoriasis360.es had the highest proportion of traffic from direct searches (97%).

Between January 2022 - December 2022, approximately 1,250 social media posts related to PsO were detected from pharma companies in EUCAN, including LEO Pharma, Amgen, Janssen, Novartis, Boehringer Ingelheim, and AbbVie. The post with the highest interaction (5%) was from LEO Pharma's Italia Facebook account and highlighted the importance of diet for PsO patients and linked to its unbranded Psopeople.it site.

Scope

This report assesses key digital marketing metrics of pharma assets in PsO, including branded websites for patients and HCPs, Unbranded websites, and social media accounts.
Metrics include website traffic volume, engagement, and source, DDA, paid SEO, and social media post interaction.
Countries include the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN).

Reasons to Buy

Understand the digital marketing competitive landscape in PsO, with a view of leading patient and HCP branded assets across different regions.
See what tactics pharma companies are using to drive traffic to their PsO branded assets for patient and HCPs, such as DDA and paid SEO.
Understand what sources of website traffic are generating the most visits to these assets, such as paid SEO, social media, or organic searches.
Compare top branded and unbranded assets for patients by how they address and support different patient needs.
See what pharma social media accounts in PsO are the most active and achieving the most engagement.